Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604412 | 0.96 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AALDH1A1TRPA1 | |
| SCHEMBL28286970 | 0.91 | — | — | |
| SCHEMBL713102 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL9966967 | 0.77 | ATM (0.42) | SMN1; SMN2MEN1KMT2AALDH1A1TRPA1 | |
| SCHEMBL265557 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL5411525 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL4862696 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL29992415 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL691739 | 0.75 | — | — | |
| SCHEMBL571438 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417825-B | Five-membered or six-membered fused ring pyrimidine cyclopropyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2024-06-28 | — | — | CN | claimed |
| CN-114874232-B | Preparation method and application of thienopyrimidinone compound containing ethyl naphthalene structure | 山东大学 | 2023-11-14 | — | — | CN | claimed |
| CN-116640095-A | Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof | 山东大学 | 2023-08-25 | — | — | CN | claimed |
| CN-115417825-A | Five-membered or six-membered fused ring pyrimidine cyclopropyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| CN-114874232-A | Preparation method and application of thienopyrimidinone compound containing ethyl naphthalene structure | 山东大学 | 2022-08-09 | — | — | CN | claimed |
| EP-4719369-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4651954-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| EP-0240256-A2 | Compounds useful in treating sickle cell anemia | MERCK & CO. INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0027948-B1 | TETRAHYDRO-FLUORENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | disclosed |
| US-4356314-A | [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4356313-A | [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4337354-A | BRAIN AND SPINAL CHORD DAMAGE | MERCK & CO., INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4317922-A | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives | MERCK & CO., INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4316043-A | ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0027948-A1 | Tetrahydro-fluorene compounds, processes for their preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | SMN1; SMN2 1439/4885MEN1 3794/4885KMT2A 3371/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | SMN1; SMN2 4360/4885MEN1 3387/4885KMT2A 4008/4885 |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, BCKDK, CYP11B2 | SMN1; SMN2 2889/4885MEN1 171/4885KMT2A 1942/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | SMN1; SMN2 138/4885MEN1 2402/4885KMT2A 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.